The 340B Drug Pricing Program is crucial for reducing drug costs for underserved populations by allowing certain healthcare providers to purchase drugs at discounted prices. However, many employers and purchasers are unaware of its impact on their healthcare costs. This lack of awareness can lead to misconceptions about the program's scope and benefits, hindering efforts to address the underlying issues related to drug pricing and access. 

Educating employers and purchasers about the 340B program's mechanics and its potential effects on overall healthcare expenses is essential. Greater understanding can foster more informed discussions and strategies to manage drug costs effectively and ensure that all stakeholders are working toward a fairer, more transparent healthcare system.